This Brief is an AI-generated synthesis of the public record. It may contain errors, omissions, or out-of-date information, and is not legal advice or original reporting. Verify against the primary sources before relying on it.

THE BRIEF: The Monsanto Roundup Litigation

SECTION 1 — VERDICT

The public record establishes that glyphosate, the active ingredient in Monsanto’s Roundup herbicide, has been the subject of sharply conflicting assessments: major regulatory bodies have repeatedly concluded that it is not likely to be carcinogenic to humans when used as directed, while the World Health Organization’s International Agency for Research on Cancer (IARC) classified it as “probably carcinogenic to humans” in 2015. A series of U.S. jury trials, upheld on appeal, have found that Roundup caused non‑Hodgkin lymphoma in specific users, and that Monsanto acted with malice or conscious disregard for safety by failing to warn about the risk. The litigation evidence, including multiple adverse jury verdicts and internal corporate documents, shows that Monsanto was aware of the cancer concerns and that its conduct was later found by courts to amount to malice and conscious disregard for safety, even as the regulatory consensus remained formally unchanged.

Indicators include the 1985 EPA classification of glyphosate as a possible human carcinogen, which was later reversed—Monsanto’s own studies from that period were subsequently found to be invalid and were repeated in accordance with EPA guidelines; internal emails showing the company planned for the IARC classification and proposed contacting EPA’s cancer‑assessment‑committee chair to manage the fallout; a peer‑reviewed study of de‑classified Monsanto documents documenting company‑sponsored ghostwriting of safety articles and interference in the peer‑review process; an internal Monsanto email describing a ghost‑writing arrangement to “keep the cost down”; the retraction of a year‑2000 paper that had been used to support glyphosate’s safety in regulatory approvals; and multiple trial and appellate findings that Monsanto ignored Roundup’s carcinogenic risks and exhibited malice or conscious disregard. No single public document contains an explicit admission that glyphosate “causes cancer,” and the major regulatory bodies continue to maintain the product is safe. This reading cannot be proven from available public evidence. It also cannot be dismissed.

What the evidence cannot establish is whether glyphosate definitively causes non‑Hodgkin lymphoma in humans at typical exposure levels, given the conflicting epidemiological record—the large Agricultural Health Study found no statistically significant association with glyphosate use for any cancer, while a 2019 meta‑analysis reported a compelling link. It also cannot establish the full extent of Monsanto’s internal knowledge or the degree to which the company’s influence altered the specific safety conclusions of any regulator. The available public record does not contain an internal Monsanto document that states plainly that glyphosate can cause cancer.

SECTION 2 — CASE SUMMARY

Glyphosate is the active ingredient in Roundup, Monsanto’s broad‑spectrum herbicide first marketed in 1974. The U.S. Environmental Protection Agency (EPA) originally registered glyphosate‑based pesticides that year and has repeatedly re‑approved Roundup labels without a cancer warning. Global glyphosate use rose dramatically after the introduction of “Roundup Ready” genetically modified crops in 1996. In March 2015, the World Health Organization’s International Agency for Research on Cancer (IARC) classified glyphosate as “probably carcinogenic to humans” (Group 2A), citing evidence for non‑Hodgkin lymphoma in some epidemiological studies and strong mechanistic data. The classification triggered a wave of personal‑injury lawsuits in the United States and intensified a long‑standing scientific dispute.

Beginning in 2018, a series of U.S. jury trials led to verdicts holding Monsanto liable for non‑Hodgkin lymphoma in plaintiffs who had used Roundup over many years. In August 2018, a California state jury awarded school groundskeeper Dewayne Johnson $289 million, which was later reduced to $20.5 million on appeal. The following year, a federal bellwether trial for Edwin Hardeman resulted in an $80 million jury verdict, which the trial judge reduced to $25 million; the Ninth Circuit affirmed that final judgment, finding that evidence showed the carcinogenic risk was knowable and that Monsanto acted with malice. That same year, a California state jury awarded Alva and Alberta Pilliod a combined $2 billion, with the appellate court noting Monsanto’s “conscious disregard for the safety of others”; the final judgment stood at roughly $86 million after judicial reductions and the U.S. Supreme Court’s denial of review. Multiple other trials yielded large punitive awards, including a $611 million Missouri judgment that an appellate court upheld in 2025, citing Monsanto’s awareness since 1985 that glyphosate “has the potential to cause cancer”. One California jury returned a defense verdict in late 2021, rejecting a plaintiff’s claim that Roundup caused her cancer.

Monsanto was acquired by Bayer AG in 2018 for $63 billion, after which Bayer’s market capitalization roughly halved as the litigation unfolded. By 2026, Bayer had paid approximately $11 billion to settle nearly 100,000 claims. In February 2026, the company announced a proposed $7.25 billion settlement to resolve most remaining U.S. cases. Meanwhile, the U.S. Supreme Court ruled in June 2026 that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state‑law failure‑to‑warn claims, effectively barring future plaintiffs from arguing that Monsanto should have added a cancer warning to Roundup’s label. The EPA, in turn, has consistently maintained that glyphosate is not likely to be carcinogenic, withdrawing interim registration decisions on procedural grounds but reaffirming its underlying scientific findings.

The case thus presents a collision between the formal regulatory safety framework—backed by the EPA, the European Chemicals Agency, and other bodies—and a litigation record in which multiple courts found that Monsanto knew about cancer risks and deliberately suppressed them.

SECTION 3 — FULL RECORD

Evidentiary Posture

The available record consists of numerous U.S. court decisions, including jury verdicts, appellate rulings, and one U.S. Supreme Court decision; regulatory determinations from the EPA, the European Chemicals Agency, and other international bodies; peer‑reviewed epidemiological and toxicological studies; internal Monsanto documents produced in discovery and made public through litigation; and a large body of news reporting and advocacy‑group statements. The record is heavily skewed by the adversarial process: key internal documents come from plaintiffs’ productions and are contested as to context, while major epidemiological analyses are critiqued by both sides. No comprehensive independent inquiry—such as a formal congressional investigation or an unredacted release of all internal Monsanto records—has been made public. The EPA Office of Inspector General is reportedly investigating potential collusion between Monsanto and EPA officials, but the outcome is unknown. The Supreme Court’s Durnell preemption ruling in 2026 has altered the legal landscape, likely curtailing future state‑law failure‑to‑warn claims, but has not resolved the underlying factual question of what Monsanto knew and when.

Observed Facts vs. Inferred Claims

Observed facts include: the EPA’s repeated conclusion that glyphosate is not likely to be carcinogenic to humans; the IARC’s 2015 classification of glyphosate as Group 2A; the specific jury verdicts and damage awards, as altered by judicial reductions, in the cases of Johnson, Hardeman, Pilliod, Durnell, McKivison, and others; the text of an internal Monsanto email discussing ghost‑writing of a paper; a peer‑reviewed study that documented Monsanto‑sponsored ghostwriting and interference in the peer‑review process in de‑classified company documents; the retraction of a year‑2000 paper by the journal Regulatory Toxicology and Pharmacology; the EPA’s 1985 classification of glyphosate as a possible human carcinogen; and the amounts and timing of Bayer’s settlement payments and proposals.

Inferred claims include: that Monsanto knew glyphosate could cause cancer and deliberately concealed that knowledge; that the company’s influence altered the specific conclusions of any regulator; that the ghost‑writing and peer‑review interference caused the safety studies to be fraudulent; that the early EPA carcinogenicity classification was reversed because of Monsanto’s influence rather than new science; and that the jury findings of malice reflect the company’s actual internal state rather than a permissible inference drawn by triers of fact. These inferred claims are supported to varying degrees by the observed facts but are not directly established by any single document in the public record.

Figure Inventory

Plaintiffs and Aggrieved Parties

• Dewayne “Lee” Johnson (DOCUMENTED; status: reported alive, unconfirmed) — groundskeeper, diagnosed with non‑Hodgkin lymphoma in 2014, obtained a judgment of $20.5 million after reductions.
• Edwin Hardeman (DOCUMENTED; status unknown) — used Roundup from the 1980s to 2012, diagnosed in 2015, obtained a final judgment of $25 million.
• Alva Pilliod (DOCUMENTED; status unknown) — diagnosed with non‑Hodgkin lymphoma in 2013 at age 69, used Roundup for about 30 years; final award (joint with Alberta) approximately $86 million.
• Alberta Pilliod (DOCUMENTED; status unknown) — diagnosed in 2017 at age 70; joint final award with Alva Pilliod.
• John Durnell (DOCUMENTED; status unknown) — sued Monsanto in Missouri, obtained a $1.25 million verdict later overturned by the U.S. Supreme Court on preemption grounds.
• Donnetta Stephens (DOCUMENTED; status unknown) — plaintiff in a California trial where the jury returned a defense verdict.
• John McKivison (DOCUMENTED; status unknown) — Philadelphia plaintiff, initially awarded $250 million compensatory and $2 billion punitive, reduced to $400 million.
• Christine Sheppard (DOCUMENTED; status unknown) — named among over 800 cancer patients who sued Monsanto.
• James Greco, Thomas Rainwater, Gary Roth, Jordan Harrison (DOCUMENTED; status unknown) — additional plaintiffs identified in the record, no further detail.

Monsanto / Bayer Executives and Associated Figures

• William Heydens (DOCUMENTED employment; allegations of specific email content CONTESTED WITH NAMED SOURCE; status unknown) — Monsanto executive; internal email discussing ghost‑writing a paper; also cited in plaintiffs’ filings regarding “IARC Planning” emails.
• Dan Jenkins (DOCUMENTED employment; allegations of specific actions CONTESTED WITH NAMED SOURCE; status unknown) — Monsanto executive; plaintiffs’ filings claim he proposed contacting EPA’s Jess Rowland.
• Dr. Parry (DOCUMENTED employment; allegations of genotoxic findings CONTESTED WITH NAMED SOURCE; status unknown) — Monsanto toxicologist; plaintiffs allege his work indicated increased genotoxic risks and that further studies were not performed.
• Jess Rowland (DOCUMENTED role at EPA; allegations of collusion CONTESTED WITH NAMED SOURCE; status unknown) — former EPA Cancer Assessment Review Committee chairman, mentioned in plaintiffs’ allegations; no further public statement in the record.
• Christopher Portier (DOCUMENTED IARC participation; bias allegation CONTESTED WITH NAMED SOURCE; status unknown) — IARC invitee; House Science Committee alleged he was a litigation consultant, implying bias; IARC director Wild defended the evaluation.

Judicial and Regulatory Officials

• Judge Vince Chhabria (DOCUMENTED; status: serving as of orders) — U.S. District Judge presiding over the Roundup multidistrict litigation (MDL No. 2741).
• Kenneth Feinberg (DOCUMENTED; status: no change noted in record) — mediator appointed by Judge Chhabria in 2019 for court‑mandated settlement talks.

All figures above are named in the record. For Monsanto executives and outside consultants, the allegations concerning their conduct are drawn from litigation documents or news reports and are not independently corroborated by any official agency finding.

Source Weighting

The sources for this Brief are weighted by their institutional credibility within their domain. At the top of the hierarchy are the formal findings of U.S. appellate courts and the U.S. Supreme Court, which establish the procedural and preemption landscape. Regulatory determinations from the EPA and the European Chemicals Agency carry significant weight within their respective regulatory areas, though the EPA’s process has been partially vacated by the Ninth Circuit and is subject to an Inspector General investigation. Peer‑reviewed scientific studies, including the IARC monograph, the Agricultural Health Study, and the study of Monsanto’s ghost‑writing practices, are treated as credible scientific sources, with the understanding that epidemiological conclusions are often contested. Documented internal company communications produced in litigation, such as the Heydens email and the allegations concerning “IARC Planning”, are informative but are viewed with the caution appropriate to adversarial productions; they are not verified by a neutral third party. News reports and advocacy‑group statements are given lower weight unless they independently corroborate facts established elsewhere in the higher‑tier sources. The jury verdicts themselves are treated as established legal facts, but the underlying inference of causation in each specific case is not independently reviewed here—the Brief reports the judicial conclusions, not the raw data those conclusions relied upon.

Anomalies

Several significant anomalies in the dominant narrative—that glyphosate is safe and Monsanto acted in accordance with regulatory science—stand out.

HIGH significance

• 1985 EPA classification reversal: In 1985, an EPA panel classified glyphosate as a possible human carcinogen based on a mouse study showing rare tumors. The classification was later reversed. Monsanto’s own studies from that period were subsequently found to be invalid and were repeated in accordance with EPA guidelines. The sequence—a possible carcinogen classification, followed by reversal after invalid studies were repeated—raises questions about the basis for the reversal and the independence of the subsequent safety determinations.
• Ghostwriting and peer‑review interference: The documented evidence that Monsanto sponsored ghost‑written articles in toxicology journals, interfered in the peer‑review process, and created an academic‑style website as a front for the defense of its products demonstrates an organized effort to shape the scientific record. This goes beyond normal corporate advocacy and undermines the reliability of the published safety literature that regulators have relied upon.
• IARC‑timing emails and EPA contact: Plaintiffs’ filings indicate that Monsanto executive Heydens discussed “IARC Planning” one month before the 2015 classification, and that Jenkins immediately proposed contacting EPA’s cancer‑review‑committee chair. The temporal and substantive convergence suggests a coordinated corporate strategy to influence a regulatory body before and after an adverse classification.
• Retraction of a regulatory‑used safety paper: The 2026 retraction by Regulatory Toxicology and Pharmacology of a year‑2000 paper that had been cited in support of glyphosate’s safety casts doubt on the integrity of the body of literature upon which some safety approvals have rested.

MODERATE significance

• IARC–EPA divergence: IARC, a WHO cancer agency, classified glyphosate as a probable human carcinogen while the EPA concluded it is not likely to be carcinogenic. This split is not merely a difference of opinion; it reflects fundamentally different methodologies and an ongoing scientific dispute. The EPA’s analysis was later vacated by a court for discounting correlative studies, though EPA reaffirmed its findings.
• Pattern of jury findings of malice: Juries in Johnson, Hardeman, Pilliod, and other cases unanimously found that Monsanto acted with malice or conscious disregard, and these findings were affirmed on appeal. While juries are not scientific bodies, the consistency of the finding across multiple trials, each with robust evidentiary records, is a significant anomaly in a narrative that describes the company as a responsible corporate actor.
• EPA OIG investigation: The reported investigation by the EPA’s Office of Inspector General into possible collusion between Monsanto and EPA officials is, by itself, a procedural step that signals potential impropriety; its outcome remains unknown, but its existence is anomalous in a routine regulatory matter.

LOW significance

• Procedural clustering of Trump‑era actions: The coincidence of an executive order promoting glyphosate production, the placement of Bayer‑linked lawyers in the administration, and the favorable Durnell ruling raises a suspicion of political alignment, but no direct evidence of a causal connection is available. The timing is noted but does not independently establish collusion.

Motive and Mechanism

Monsanto’s motive was overwhelmingly financial. Glyphosate, as the active ingredient in Roundup and the cornerstone of the “Roundup Ready” crop system, generated enormous revenue; the product’s global market expanded dramatically after 1996. The 1985 EPA classification as a possible carcinogen created an early existential threat to the product’s future, and a cancer warning would have devastated sales and invited worldwide regulatory restrictions. After Bayer acquired Monsanto for $63 billion, the liability exposure from cancer lawsuits became a material threat to the parent company’s financial health, halving its market capitalization. The intense financial pressure to avoid a cancer label persisted throughout.

The mechanism for maintaining the product’s regulatory safety image was not a single overt act but a sustained, multi‑pronged corporate strategy. The de‑classified documents and peer‑reviewed study indicate that Monsanto sponsored ghost‑written articles in toxicology journals, interfered in the peer‑review process, and operated an academic‑looking website to disseminate pro‑Monsanto material. The internal email from executive Heydens about keeping costs down by having the company write a paper and having outside academics “just edit & sign their names” shows a direct method for populating the scientific literature with favorable content. The alleged emails regarding “IARC Planning” and the proposal to contact EPA’s cancer‑committee chair suggest a coordinated effort to anticipate and manage regulatory dead‑letter offices. These actions, taken together, allowed Monsanto to maintain the appearance of a robust safety consensus while suppressing contrary evidence. The repeated jury findings of malice and conscious disregard are consistent with the inference that the company’s strategy was deliberate.

Competing Theories

Theory	Key Proponents	Indicative Evidence	Confidence
Glyphosate is safe when used as directed; IARC classification is flawed and litigation is unfounded	EPA, ECHA, Monsanto/Bayer	EPA’s “not likely to be carcinogenic” finding; Agricultural Health Study null results; ECHA conclusion that carcinogen classification is not justified	LOW‑TO‑MODERATE. The theory has strong institutional backing but is undercut by the documented ghost‑writing, the retracted paper, and the multiple court findings of malice.
IARC’s classification is correct; glyphosate is probably carcinogenic, but Monsanto’s knowledge and concealment are uncertain	Some independent scientists	IARC monograph; 2019 meta‑analysis; jury findings of causation in individual cases	MODERATE. The carcinogenicity evidence is scientifically contested, and while IARC’s classification is credible, the extent of Monsanto’s foreknowledge beyond the 1985 signal is not fully proven.
Monsanto systematically concealed known carcinogenic risk	Plaintiffs, multiple juries, Ninth Circuit, Missouri Court of Appeals	Jury findings of malice/conscious disregard; ghost‑writing email; peer‑reviewed study of ghostwriting and peer‑review interference; alleged “IARC Planning” emails; 1985 carcinogen classification and its later reversal; retracted safety paper	STRONG CIRCUMSTANTIAL (see dedicated section below). The accumulation of indicators is significant, but a direct internal corporate admission is absent from the public record.
The entire Roundup litigation is a legal‑extortion scheme driven by plaintiffs’ lawyers	Some industry commentators	Defense verdict in Stephens case; Monsanto’s statement that consensus among regulators is that glyphosate is safe; Supreme Court preemption ruling limiting future claims	LOW. While one jury returned a defense verdict, the weight of the litigation record and the appellate affirmances do not support a characterization of the litigation as baseless.

The reading that Monsanto knew glyphosate‑based Roundup could cause cancer and systematically worked to suppress that risk from regulators and the public rests on a constellation of documented indicators, none of which individually proves the case but which together form a pattern that multiple courts have found to amount to malice or conscious disregard.

Indicators

1. 1985 EPA classification and its reversal. In 1985, an EPA panel classified glyphosate as a possible human carcinogen based on a mouse study showing rare kidney tumors and malignant lymphomas. The classification was later withdrawn. Monsanto’s own studies from that period were subsequently found to be invalid and were repeated in accordance with EPA guidelines. A Missouri appellate court noted in 2025 that “Monsanto has been aware since 1985 that glyphosate… has the potential to cause cancer”. This early regulatory signal, never acted upon with a label change, gave the company decades of notice that independent scientists saw a cancer concern.

2. Documented ghostwriting and scientific interference. A peer‑reviewed study of de‑classified Monsanto documents found “Monsanto‑sponsored ghostwriting of articles published in toxicology journals and the lay media, interference in the peer review process, behind‑the‑scenes influence on retraction and the creation of a so‑called academic website as a front for the defense of Monsanto products”. An internal email from executive William Heydens described a ghost‑writing arrangement that would “keep the cost down” by having Monsanto write a paper and having outside scientists “just edit & sign their names so to speak”. These records show a deliberate corporate effort to populate the scientific literature with favorable content while concealing Monsanto’s hand.

3. Retraction of a safety paper. In 2026, the journal Regulatory Toxicology and Pharmacology retracted a year‑2000 paper that had been used to support glyphosate safety in regulatory approvals. Although the precise reason for the retraction is not confirmed by an official journal statement in this record, the paper’s use in the safety record and its later retraction erode the reliability of the body of literature underlying the “safe” conclusion.

4. Internal emails and coordination with regulators. Plaintiffs’ filings indicate that Heydens discussed “IARC Planning” about one month before the March 2015 IARC classification, and that after the report appeared, he proposed work needed to “deal with the IARC fallout” while executive Dan Jenkins proposed contacting Jess Rowland, then chairman of the EPA’s Cancer Assessment Review Committee. The content and timing of these messages, albeit unverified by an independent body, are precisely what one would expect if a company were orchestrating a response to an adverse scientific finding by influencing a key regulator.

5. Consistent jury findings of malice and conscious disregard. In trials with full evidentiary records, juries in Johnson, Hardeman, and Pilliod (among others) found that Monsanto acted with malice or conscious disregard for safety. The Ninth Circuit specifically held that “substantial evidence was presented that Monsanto acted with malice by, among other things, ignoring Roundup’s carcinogenic risks”. The California Court of Appeal, in affirming the Pilliod verdict, stated that Monsanto showed “conscious disregard for the safety of others”. A Missouri appellate court similarly condemned Monsanto’s “high” degree of reprehensibility. These are not isolated findings; they are a pattern across multiple jurisdictions and years, each resting on the same body of internal documents and expert testimony.

6. Absence of a voluntary cancer warning despite decades of knowledge. Despite the 1985 EPA classification, the IARC classification, and the internal discussions about managing the fallout, Monsanto never sought to add a cancer warning to Roundup’s label, and EPA never required one. A company genuinely uncertain about the risk would be expected to exercise caution; Monsanto’s steadfast refusal, combined with the evidence of scientific influence, is consistent with a strategic decision to avoid any acknowledgment that could be used in litigation or regulation.

7. Financial motive of exceptional magnitude. The product’s enormous profitability, the near‑15‑fold increase in global use after 1996, and the $63 billion acquisition by Bayer created an intense financial incentive to suppress any cancer link. Bayer’s halving market capitalization and its subsequent $11 billion in settlements confirm that a cancer label would have been catastrophic for the business.

What is missing is a single document in the public record—a memo, an email, or a sworn statement—in which a Monsanto official states plainly that “glyphosate causes cancer” or admits a scheme to conceal. The internal emails that are public show planning and influence, but not an explicit acknowledgment of the underlying harm. The exact degree to which the company’s activities altered any specific regulator’s conclusion is also not independently established; the EPA maintains its science despite the Ninth Circuit’s partial vacatur.

This reading cannot be proven from available public evidence. It also cannot be dismissed.

What the Evidence Best Supports

The evidence best supports the finding that Monsanto was aware of significant scientific signals that glyphosate could cause cancer and undertook a sustained effort to prevent that risk from being reflected in the regulatory record and on its product label. The combination of the 1985 EPA carcinogen classification, the internal ghost‑writing and peer‑review interference, the emails showing coordination around the IARC report and contact with EPA officials, the retraction of a safety paper, and the uniform findings of malice by multiple juries and appellate courts makes it more probable than not that the company’s conduct was not merely negligent but deliberate. The regulatory safety assessments that continue to support Roundup are thus not independent; they were produced and maintained in an environment demonstrably shaped by Monsanto’s scientific influence.

The available evidence does not, however, permit a definitive conclusion that glyphosate causes non‑Hodgkin lymphoma at typical exposure levels, given the conflicting epidemiological data. Nor does it permit a precise quantification of how much Monsanto’s actions affected the specific conclusions of the EPA or other bodies. What it does support is that Monsanto’s behavior—the concealment and the influence—was inconsistent with a good‑faith reliance on safety science.

SECTION 4 — WHAT REMAINS UNKNOWN

Several central questions remain unresolved. The outcome of the EPA Office of Inspector General investigation into potential collusion between Monsanto and EPA officials is unknown, and its findings could significantly alter the assessment of the agency’s independence. The precise reason for the retraction of the year‑2000 safety paper is not confirmed by a journal statement, leaving open the possibility that the retraction was for reasons unrelated to the science itself. The full extent of Monsanto’s internal knowledge—what individual executives believed and when—remains opaque; the public record contains no explicit admission. The final disposition of the proposed $7.25 billion settlement, particularly after the Durnell preemption ruling and the remand to state court, is unresolved. The financial impact of the Durnell decision on existing settlements and pending claims is not yet captured in the record. Finally, the exact number of pending claims fluctuates between sources and is not fixed by the current record.

SECTION 5 — METHODOLOGICAL NOTE

The central difficulty in this case is that two robust institutional records—the formal safety determinations of major regulatory bodies and the litigation‑driven findings of multiple U.S. courts—point in opposite directions. No single document bridges them: the regulators rely on a record of science that the litigation record suggests was partly manufactured by the company being regulated, while the courts have inferred malice from the same pattern of conduct without direct proof of the internal state of every actor. The result is a situation in which the public record is rich with indicia of corporate suppression but lacks the kind of admission that would collapse the dispute. The case remains open not because the evidence is thin, but because the most critical facts are locked inside the internal records of a corporation that has never voluntarily disclosed them.